biology

Obecabtagene autoleucel

Obecabtagene autoleucel is a biology topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Obecabtagene autoleucel rather than just read about it. In short: Obecabtagene autoleucel, sold under the brand name Aucatzyl, is an anti-cancer medication used for the treatment of acute lymphoblastic leukemia. It is a CD19-directed genetically modified autologous T-cell immunotherapy.

Key takeaways

Obecabtagene autoleucel belongs to biology; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Obecabtagene autoleucel to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Obecabtagene autoleucel from memory before moving on to harder problems.

Reference excerpt

Obecabtagene autoleucel, sold under the brand name Aucatzyl, is an anti-cancer medication used for the treatment of acute lymphoblastic leukemia. It is a CD19-directed genetically modified autologous T-cell immunotherapy. The most common side effects include cytokine release syndrome, infections-pathogen unspecified, musculoskeletal pain, viral infections, fever, nausea, bacterial infectious disorders, diarrhea, febrile neutropenia, immune effector cell-associated neurotoxicity syndrome, hypotension, pain, fatigue, headache, encephalopathy, and hemorrhage. Obecabtagene autoleucel was approved for medical use in the United States in November 2024.

Medical uses Obecabtagene autoleucel is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Side effects The US Food and Drug Administration (FDA) approved prescribing information for obecabtagene autoleucel has a boxed warning for cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and T-cell malignancies. The most common side effects include cytokine release syndrome, infections-pathogen unspecified, musculoskeletal pain, viral infections, fever, nausea, bacterial infectious disorders, diarrhea, febrile neutropenia, immune effector cell-associated neurotoxicity syndrome, hypotension, pain, fatigue, headache, encephalopathy, and hemorrhage.

History Efficacy was evaluated in FELIX (NCT04404660), an open-label, multicenter, single-arm trial that enrolled adults with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia. Enrolled participants were required to have relapsed following a remission lasting twelve months or less, relapsed or refractory acute lymphoblastic leukemia following two or more prior lines of systemic therapy, or disease that was relapsed or refractory three or more months after allogeneic stem cell transplantation. The major efficacy outcome measures were rate and duration of complete remission achieved within three months after infusion. Additional outcome measures were rate and duration of overall complete remission which includes complete remission and complete remission with incomplete hematologic recovery, at any time. Of the 65 participants evaluable for efficacy, 27 participants (42%; 95% confidence interval [CI]: 29%, 54%) achieved complete remission within three months. The median duration of complete remission achieved within three months was 14.1 months (95% CI: 6.1, not reached). The US Food and Drug Administration (FDA) granted the application for obecabtagene autoleucel regenerative medicine advanced therapy (RMAT) and orphan drug designations.

Society and culture

Legal status Obecabtagene autoleucel was approved for medical use in the United States in November 2024. In May 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Aucatzyl, intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor acute lymphoblastic leukemia. The applicant for this medicinal product is Autolus GmbH. Obecabtagene autoleucel was authorized for medical use in the European Union in July 2025.

Names Obecabtagene autoleucel is the international nonproprietary name. It is sold under the brand name Aucatzyl.

References

External links "Obecabtagene autoleucel (Code C172746)". NCI Thesaurus. Archived from the original on 10 November 2024. Clinical trial number NCT04404660 for "A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)" at ClinicalTrials.gov

Worked examples

Example 1 — a first encounter with Obecabtagene autoleucel

Start with the simplest possible case. Write down what Obecabtagene autoleucel claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In biology, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Obecabtagene autoleucel before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Obecabtagene autoleucel ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Obecabtagene autoleucel

In research: Obecabtagene autoleucel appears in biology research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Obecabtagene autoleucel in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Obecabtagene autoleucel is common in secondary-school and first-year university syllabi. It links to neighbouring topics Antineoplastic drugs, Approved gene therapies, CAR T-cell therapy, so understanding it makes those chapters shorter.
In everyday life: Look for Obecabtagene autoleucel outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Obecabtagene autoleucel in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Obecabtagene autoleucel means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Obecabtagene autoleucel out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Obecabtagene autoleucel in simple terms?

Why does Obecabtagene autoleucel matter?

Because it connects several biology ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Obecabtagene autoleucel?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Obecabtagene autoleucel.